Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20262983 | 0.98 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL7323517 | 0.93 | MMP1 (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL7323504 | 0.90 | MMP1 (0.34) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL11269500 | 0.71 | KDM4E (0.38) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL9614868 | 0.67 | — | — | |
| SCHEMBL6850234 | 0.66 | — | — | |
| SCHEMBL11499500 | 0.65 | KDM4E (0.41) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL29582415 | 0.64 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL9866206 | 0.63 | KDM4E (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| Hydrochloric Acid SCHEMBL28618463 | 0.63 | KDM4E (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563126-A1 | HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | claimed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| EP-2126053-A2 | APOCRINE CELL LINE | Unilever PLC (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116713-A2 | APOCRINE CELL LINE | UNILEVER PLC (GB) | 2008-10-02 | — | — | WO | disclosed |
| CN-1128148-C | Process for the synthesis of (1H)-benzo [C] quinolizin-3-ones derivatives | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-19 | — | — | CN | disclosed |
| CN-1311788-A | Process for the synthesis of (1H)-benzo [C] quinolizin-3-ones derivatives | APPLIED RESEARCH SYSTEMS (NL) | 2001-09-05 | — | — | CN | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1998025930-A2 | USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-18 | — | — | WO | disclosed |